drugset
drugset / Trial / NCT06460961

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

NCT06460961 ↗

Phase 1 Active not recruiting 168 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.

Timeline

Start
2024-07-14
Primary completion
2027-07-13
Completion
2027-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-6837 Unknown — Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Acetaminophen Small molecule — —
Background Dexamethasone Small molecule — —

Indications

metastatic malignant neoplasm